PF-562271

Name: PF-562271
Brand: Selleck Chemicals
SKU: S2890
Rating: 5 (78 reviews)

For research use only.

Catalog No.S2890

78 publications

CAS No. 717907-75-0

PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

Selleck's PF-562271 has been cited by 78 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(5):2422-2434

PubMed: 32250340 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3282

PubMed: 32612176 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2020, 15

PubMed: 32485098 ( click the link to review the publication )

Cell Rep, 2020, 30(6):1780-1797

PubMed: 32049010 ( click the link to review the publication )

Elife, 2020, 4;9:e50571

PubMed: 32017701 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Sci Rep, 2020, 10(1):419

PubMed: 31942012 ( click the link to review the publication )

J Biol Chem, 2020, 12 pii: jbc

PubMed: 32280065 ( click the link to review the publication )

Cell Cycle, 2020, 14:1-13

PubMed: 32286145 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31905606 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Sci Signal, 2019, 12(565)

PubMed: 30670633 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):738

PubMed: 31570694 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1461-1469

PubMed: 31006845 ( click the link to review the publication )

Molecules, 2019, 24(10)

PubMed: 31109130 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, 168:163-173

PubMed: 30807921 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):4753-4760

PubMed: 31059085 ( click the link to review the publication )

Zygote, 2019, 27(3):173-179

PubMed: 31171046 ( click the link to review the publication )
Cell Rep, 2018, 22(10):2784-2796

PubMed: 29514104 ( click the link to review the publication )

Oncogene, 2018, 37(22):2953-2966

PubMed: 29515233 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):848

PubMed: 30154481 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3783-3793

PubMed: 30281878 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(18):e008604

PubMed: 30371220 ( click the link to review the publication )

J Cell Sci, 2018, 131(10)

PubMed: 29678906 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:2190657

PubMed: 30275837 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 10.1038/aps

PubMed: 29417941 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2325-2333

PubMed: 30106432 ( click the link to review the publication )

Cancer Epidemiol Biomarkers Prev, 2018, 27(7):805-813

PubMed: 29654156 ( click the link to review the publication )

Sci Transl Med, 2017, 9(420)

PubMed: 29237758 ( click the link to review the publication )

Nat Commun, 2017, 8:14122

PubMed: 28098159 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1347-1356

PubMed: 28406574 ( click the link to review the publication )

FEBS J, 2017, 284(17):2856-2869

PubMed: 28665039 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4032

PubMed: 28642549 ( click the link to review the publication )

Mol Carcinog, 2017, 56(12):2558-2565

PubMed: 28667800 ( click the link to review the publication )

Cancer Manag Res, 2017, 9:879-889

PubMed: 29276408 ( click the link to review the publication )

Cell Signal, 2017, 38:1-9

PubMed: 28647573 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):63-70

PubMed: 28560386 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5817-5826

PubMed: 29263678 ( click the link to review the publication )
Evid Based Complement Alternat Med, 2017, 2017:4535326

PubMed: 29234400 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):8937-8943

PubMed: 28990104 ( click the link to review the publication )

Oncotarget, 2017, 8(43):75102-75113

PubMed: 29088849 ( click the link to review the publication )

Biophys J, 2017, 113(7):1585-1598

PubMed: 28844472 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(2):168-80

PubMed: 26689676 ( click the link to review the publication )

Nat Commun, 2016, 7:10354

PubMed: 26838601 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(23):5851-5863

PubMed: 27220963 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):81

PubMed: 27495308 ( click the link to review the publication )

Oral Oncology, 2016, 10.1016/j.oraloncology.2016.05.010

PubMed: ( click the link to review the publication )

Sci Rep, 2016, 6:36214

PubMed: 27796369 ( click the link to review the publication )

J Biol Chem, 2016, 291(15):8140-9

PubMed: 26865633 ( click the link to review the publication )

Mol Pharmacol, 2016, 89(5):521-40

PubMed: 26895766 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4369-4386

PubMed: 27762562 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 71:62-71

PubMed: 26693891 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48093-48106

PubMed: 27344177 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45186-45198

PubMed: 27286256 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(11):1412-21

PubMed: 26436690 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26274564 ( click the link to review the publication )

Oncogene, 2015, 34(40):5114-27

PubMed: 25639872 ( click the link to review the publication )

Cell Physiol Biochem, 2015, 37(2):515-26

PubMed: 26330161 ( click the link to review the publication )

J Biol Chem, 2015, 290(14):8677-92

PubMed: 25713079 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2015, 39(1):114-24

PubMed: 25481308 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2015, 112(20):E2595-601

PubMed: 25941386 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25755-69

PubMed: 26342198 ( click the link to review the publication )

Oncotarget, 2015, 6(3):1531-43

PubMed: 25605238 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Int J Clin Exp Pathol, 2013, 6(10):2082-91

PubMed: 24133586 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Description

Targets

FAK ^[1] (Cell-free assay)	PYK2 ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	CDK3/CyclinE ^[1] (Cell-free assay)	CDK1/CyclinB ^[1] (Cell-free assay)	View More
1.5 nM	13 nM	30 nM	47 nM	58 nM	View More

In vitro

PF-562271 binds in the ATP-binding cleft of FAK, forming two of the three “canonical” H-bonds between the inhibitor and main-chain atoms in the kinase hinge region. PF-562271 is potent in an inducible cell-based assay measuring phospho-FAK with IC50 of 5 nM. PF-562271 (3.3 μM) results in G1 arrest of PC3-M cells. ^[1] PF-562271 (1 nM) blocks bFGF-stimulated blood vessel angiogenesis as performed in chicken chorioallantoic membrane assays. PF-262271 potently blocks blood vessel sprouting without detectable changes in vascular leakage. ^[2] PF-562271 (250 nM) results in complete inhibition of collective A431 cell invasion into collagen gels. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXXTWM2OD1yLkK3OlYh\|ryP	MUfTRW5ITVJ?
SW982	NWmxXXB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEP2[IhKSzVyPUCuN\|I5OiEQvF2=	M3;lO3NCVkeHUh?=
KM12	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDVRXVKSzVyPUCuN\|g2PTdizszN	NVvPN4FZW0GQR1XS
COLO-205	NWH1XYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwNEi2OVgh\|ryP	MnnWV2FPT0WU
COLO-829	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTzXpFKSzVyPUCuO\|UyPzZizszN	NUPNOHR4W0GQR1XS
MG-63	NWjVco9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq1VJlqUUN3ME2wMlgxPjN5IN88US=>	MkPuV2FPT0WU
IGROV-1	NFfBWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTQUXVKSzVyPUCuPFExOzhizszN	MmLHV2FPT0WU
NCI-H650	NYrXdmROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\6Z2JKSzVyPUCuPFMyPTRizszN	Mn3TV2FPT0WU
RT-112	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\kTWM2OD1yLkm4OFYh\|ryP	NFqxfnRUSU6JRWK=
BCPAP	NITQR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\LTWM2OD1zLkCxNlg5KM7:TR?=	MnHxV2FPT0WU
ALL-PO	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIW1dFBKSzVyPUGuNFE2QDRizszN	MVPTRW5ITVJ?
KYSE-270	NWHIPIlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mli3TWM2OD1zLkC0O\|E1KM7:TR?=	M3XPbHNCVkeHUh?=
8305C	MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFwMEm5NFQh\|ryP	MoHUV2FPT0WU
NCI-H810	NILJVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXBTWM2OD1zLkGwO\|c3KM7:TR?=	MXrTRW5ITVJ?
CAL-33	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1v0N2lEPTB;MT6xNlk{QCEQvF2=	NGnIfZpUSU6JRWK=
AN3-CA	NFPFUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnzc4JIUUN3ME2xMlIyQDZ5IN88US=>	NEHHfoZUSU6JRWK=
NKM-1	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nxWGlEPTB;MT6yO\|UxPiEQvF2=	NEXUSlJUSU6JRWK=
BPH-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnRTWM2OD1zLkK4O\|Y3KM7:TR?=	Mme0V2FPT0WU
MES-SA	NGHjR\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPoTWM2OD1zLkOwOlgzKM7:TR?=	NVXVSZpuW0GQR1XS
CAL-62	M3zGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfjd5ZZUUN3ME2xMlMyQTB7IN88US=>	MVHTRW5ITVJ?
Detroit562	NYfr[ZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfTUW1EUUN3ME2xMlM2OjJ{IN88US=>	MmjnV2FPT0WU
KYSE-150	M4XsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TrfWlEPTB;MT6zOVI{PiEQvF2=	NYrPUowyW0GQR1XS
SK-UT-1	M4DsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XSZWlEPTB;MT60OFY1PyEQvF2=	NVnLRVZPW0GQR1XS
HUTU-80	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTFwNES4PFYh\|ryP	MWjTRW5ITVJ?
SIG-M5	M{\1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH6wN4lKSzVyPUGuOFg{QDdizszN	MkjDV2FPT0WU
AGS	M1zPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTFwNUKxNlQh\|ryP	M1SwW3NCVkeHUh?=
ST486	MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrERYJrUUN3ME2xMlU{Ojd6IN88US=>	M1fUZXNCVkeHUh?=
HSC-2	NYri[XJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFO3ZlVKSzVyPUGuOVM6PSEQvF2=	NWq1VGlnW0GQR1XS
LCLC-103H	NEXRcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvVN2FKSzVyPUGuOVU5OThizszN	MonvV2FPT0WU
BC-1	NWr1eWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jUfmlEPTB;MT62NVY3PCEQvF2=	NETOS5BUSU6JRWK=
CGTH-W-1	NEj4RXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XWeGlEPTB;MT62NVY4QSEQvF2=	MYXTRW5ITVJ?
MZ1-PC	M{KxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHyTWM2OD1zLk[yN\|EzKM7:TR?=	NXXIVJFWW0GQR1XS
SW1710	MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DuZmlEPTB;MT62NlYzQCEQvF2=	MWnTRW5ITVJ?
EW-13	NWPqZotWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTFwNkO0OlYh\|ryP	M3rje3NCVkeHUh?=
TE-11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnn0TWM2OD1zLk[zOVIzKM7:TR?=	NHfFVG5USU6JRWK=
BHY	NH2yO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTFwNkW2OlMh\|ryP	MkLNV2FPT0WU
ML-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3k[3VKUUN3ME2xMlY3QDB{IN88US=>	NGPaeHpUSU6JRWK=
MEL-JUSO	NVTjU3VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfYPXF6UUN3ME2xMlczQDlzIN88US=>	NYXs[\|EzW0GQR1XS
U251	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTPWGpXUUN3ME2xMlc1ODNzIN88US=>	NWjhOI5{W0GQR1XS
MHH-ES-1	NFnYVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVK1U4I1UUN3ME2xMlc6PTZ6IN88US=>	MYPTRW5ITVJ?
CAL-85-1	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFqzRm1KSzVyPUGuPFA1QSEQvF2=	NWrxd5RoW0GQR1XS
D-336MG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzOWlVRUUN3ME2xMlg2PjF2IN88US=>	NFq3fnRUSU6JRWK=
VA-ES-BJ	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3T0N2lEPTB;MT65NFMyPSEQvF2=	M{T4R3NCVkeHUh?=
MDA-MB-468	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFwOUGyO\|Ih\|ryP	NHrCTIZUSU6JRWK=
MEL-HO	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFwOUe5PVMh\|ryP	MnKzV2FPT0WU
SW954	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P6[GlEPTB;Mj6wNFE2OSEQvF2=	NF3Jdm5USU6JRWK=
LB831-BLC	NEnoTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUiwSI1XUUN3ME2yMlAxQTh6IN88US=>	MXTTRW5ITVJ?
EW-16	NEXFSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[1ZYxnUUN3ME2yMlA{QTh\|IN88US=>	NHTEXGxUSU6JRWK=
NCI-H460	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HOSGlEPTB;Mj6wOFg{QSEQvF2=	NFe1eI5USU6JRWK=
CHP-212	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\TSWlEPTB;Mj6wPVU{QSEQvF2=	MWnTRW5ITVJ?
MHH-NB-11	NFLJbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTJwMUK4NVgh\|ryP	MoTuV2FPT0WU
DU-4475	NWPoeWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXH0[4lDUUN3ME2yMlE1PzV7IN88US=>	MX;TRW5ITVJ?
ABC-1	NYPldItnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PRfWlEPTB;Mj6yOVE6PiEQvF2=	NE\teFFUSU6JRWK=
LOUCY	NXTubJBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXYc2xKSzVyPUKuNlYyOjhizszN	MUDTRW5ITVJ?
LC-2-ad	NF\KfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzwVVVKSzVyPUKuNlY6PjZizszN	MVnTRW5ITVJ?
ETK-1	M{nOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHrUHU4UUN3ME2yMlI5PDZizszN	M3PEW3NCVkeHUh?=
KYSE-180	M3nwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnJeW1KSzVyPUKuNlg5PzRizszN	NUO1U3BDW0GQR1XS
HOP-92	NEe2R4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi2U3l2UUN3ME2yMlMxPjd\|IN88US=>	NIrxWplUSU6JRWK=
RCC10RGB	NIPLfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzzTWM2OD1{LkOyOVA4KM7:TR?=	NXHLe\|RTW0GQR1XS
KASUMI-1	NHPaS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTJwM{K4PEDPxE1?	NHPSUnZUSU6JRWK=
ACN	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvz[mNKSzVyPUKuN\|Q4PDVizszN	NV3rToM6W0GQR1XS
BxPC-3	M2nKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTJwM{W0N\|Yh\|ryP	Mlv4V2FPT0WU
MONO-MAC-6	NFzIOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYD1bG0yUUN3ME2yMlQyOjR6IN88US=>	NY\sTnRSW0GQR1XS
CAL-39	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;vTWM2OD1{LkSxOlI5KM7:TR?=	MmnmV2FPT0WU
CMK	M1zoZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T1[mlEPTB;Mj60NVc6PSEQvF2=	MV\TRW5ITVJ?
MFE-296	M2TzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHiWGtGUUN3ME2yMlQ4Pzl{IN88US=>	NGL3Zm5USU6JRWK=
DU-145	NInVfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTJwNEmxNVgh\|ryP	MW\TRW5ITVJ?
MDA-MB-231	M33Zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPtTItMUUN3ME2yMlQ6PTd{IN88US=>	MmXXV2FPT0WU
EFO-27	NIXhZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\qPZFxUUN3ME2yMlUyQDh6IN88US=>	NWfC[FlKW0GQR1XS
SNU-387	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDzTWM2OD1{LkWyPFIh\|ryP	MXrTRW5ITVJ?
KYSE-410	Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTJwNU[1NVch\|ryP	M2fSPHNCVkeHUh?=
NCCIT	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFP0VVZKSzVyPUKuOVczPCEQvF2=	M{PkbHNCVkeHUh?=
LXF-289	M1ywTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HxR2lEPTB;Mj61PFI4OyEQvF2=	NX3yPFB1W0GQR1XS
HMV-II	MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTJwNUi5PVch\|ryP	NXj3V2YzW0GQR1XS
MOLT-4	NWDzOG9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVr2fZZ1UUN3ME2yMlYxPzF{IN88US=>	MWXTRW5ITVJ?
KOSC-2	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{OySmlEPTB;Mj62N\|g4QSEQvF2=	NXXnRmNFW0GQR1XS
TUR	M13aXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFj1T2VKSzVyPUKuOlU{PjlizszN	NYC2ZohpW0GQR1XS
NCI-H2087	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVO1W\|hbUUN3ME2yMlcyPjR4IN88US=>	NX;oSmViW0GQR1XS
SCC-15	M1;memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJwN{WyOVIh\|ryP	MULTRW5ITVJ?
HSC-4	M1LTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTJwN{izPFkh\|ryP	NIDlZnZUSU6JRWK=
G-402	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDQTWM2OD1{LkixOFQ4KM7:TR?=	M{jhV3NCVkeHUh?=
GP5d	NGHZdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[1XmtKSzVyPUKuPFM5OjdizszN	NEDsb25USU6JRWK=
IGR-1	M1;3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vUPGlEPTB;Mj64N\|k5PyEQvF2=	NWH4RnhiW0GQR1XS
SK-PN-DW	NGr5[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PuZmlEPTB;Mj64OlIxPCEQvF2=	NWjnOVE2W0GQR1XS
OPM-2	MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnjTWM2OD1{Lki5PVc5KM7:TR?=	MVzTRW5ITVJ?
5637	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jSbGlEPTB;Mj65NlQ{QSEQvF2=	MYnTRW5ITVJ?
NCI-H2030	M{XjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTJwOUiwNlkh\|ryP	M4rQc3NCVkeHUh?=
SK-LU-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfCfZVMUUN3ME2yMlk5OzN2IN88US=>	NF7WZmFUSU6JRWK=
EW-18	M2[xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHVZZBKSzVyPUOuNFU{OiEQvF2=	MnPRV2FPT0WU
786-0	NFrKTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHw[HI6UUN3ME2zMlA2Pzh2IN88US=>	MnvmV2FPT0WU
NCI-H1963	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPHTWM2OD1\|LkC4PFI2KM7:TR?=	MWDTRW5ITVJ?
A2780	NEDXXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTNwMUCzOFEh\|ryP	NFzKUXdUSU6JRWK=
NCI-H526	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXX0N2lEUUN3ME2zMlE{QTZzIN88US=>	NWPo[FBWW0GQR1XS
BHT-101	NHHpR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTNwMUW3PVgh\|ryP	M1vuVnNCVkeHUh?=
RPMI-7951	NHvLcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnriTWM2OD1\|LkKwNVM4KM7:TR?=	NFXucHlUSU6JRWK=
HL-60	NXi4fWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfVTWM2OD1\|LkKxNVQh\|ryP	NU\BVZVFW0GQR1XS
CTV-1	NF3MSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHuxNJJKSzVyPUOuNlU{PzdizszN	Mlz2V2FPT0WU
IST-SL1	Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTNwMkm0OlUh\|ryP	NFm0WJNUSU6JRWK=
G-401	NVj5dm9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnPW4pjUUN3ME2zMlI6QDB6IN88US=>	NEPlOYdUSU6JRWK=
OVCAR-5	NFmyVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPsdZkzUUN3ME2zMlM3OzV{IN88US=>	MlvOV2FPT0WU
EW-1	MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojiTWM2OD1\|LkSwOVQ1KM7:TR?=	NXrUVlB6W0GQR1XS
H4	NYnZZVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LiWmlEPTB;Mz60O\|U3QSEQvF2=	M4\udHNCVkeHUh?=
EM-2	M{PhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\lTWM2OD1\|LkS4Olc1KM7:TR?=	NGGwR2VUSU6JRWK=
RS4-11	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\pT3JKSzVyPUOuOFg4OTVizszN	MWXTRW5ITVJ?
NOMO-1	M3zhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULY[IZOUUN3ME2zMlQ6OjB2IN88US=>	NH2yRYdUSU6JRWK=
HCT-116	NXr6SlZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfZVoFKSzVyPUOuOVA4OTFizszN	NVP2cFFQW0GQR1XS
CAL-120	NEjxRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PkZ2lEPTB;Mz61O\|M2KM7:TR?=	NFO5VIxUSU6JRWK=
CAL-51	M2\3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmewTWM2OD1\|LkW3OlEzKM7:TR?=	NXPzRpd5W0GQR1XS
RVH-421	MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\IfopKSzVyPUOuOlA{OTFizszN	NEDUbJdUSU6JRWK=
NCI-H2081	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XCNWlEPTB;Mz62OVI5QCEQvF2=	MYHTRW5ITVJ?
SBC-5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPl[HltUUN3ME2zMlY4QDh{IN88US=>	NEn3UJFUSU6JRWK=
RL95-2	NX\ld2Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFP4VVdKSzVyPUOuO\|E5PjRizszN	NVTqeFRqW0GQR1XS
SW872	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TTUmlEPTB;Mz63Olk2QCEQvF2=	NVy5NXU2W0GQR1XS
VM-CUB-1	M1TPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnYVVVKSzVyPUOuO\|c2OSEQvF2=	MXLTRW5ITVJ?
SUP-T1	M2Du[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTNwN{izNkDPxE1?	NVvBUotxW0GQR1XS
697	NYr5OpRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Xr[WlEPTB;Mz64NVY2PyEQvF2=	MnPiV2FPT0WU
DBTRG-05MG	M2rHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrycpJGUUN3ME2zMlgyPjd4IN88US=>	MnvtV2FPT0WU
TE-441-T	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEH6NGhKSzVyPUOuPFI6OyEQvF2=	MkLVV2FPT0WU
A204	Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NISzdHZKSzVyPUOuPVA6PTZizszN	NUXObm5jW0GQR1XS
HCC2998	MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLlTWM2OD1\|Lkm0PFQ{KM7:TR?=	NUi2VGVXW0GQR1XS
SCC-4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TwTGlEPTB;Mz65OVc5OiEQvF2=	MXXTRW5ITVJ?
ACHN	MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvUTWM2OD12LkCyN\|ch\|ryP	NX;mdWFLW0GQR1XS
NB1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLrTlVKSzVyPUSuNFY3PDRizszN	NFnkephUSU6JRWK=
PANC-08-13	NH;nc\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXofnJKSzVyPUSuNFc4OyEQvF2=	MXjTRW5ITVJ?
A4-Fuk	M1rJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTRwMEe4OlEh\|ryP	NV\MNFhRW0GQR1XS
NCI-H747	NEjqPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LXZWlEPTB;ND6wPFY4PCEQvF2=	NVq1TnNEW0GQR1XS
G-361	M1\4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrN[pBxUUN3ME20MlA6ODZizszN	MXHTRW5ITVJ?
NCI-H292	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HKNWlEPTB;ND6wPVQzQSEQvF2=	M3y3c3NCVkeHUh?=
HGC-27	NETPU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHRVYRKSzVyPUSuNFk2PDlizszN	MoH3V2FPT0WU
ATN-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXwSVBJUUN3ME20MlExPzd5IN88US=>	MYfTRW5ITVJ?
RPMI-2650	NH7FdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkW1TWM2OD12LkGyPVc2KM7:TR?=	M161TnNCVkeHUh?=
SIMA	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPVcpVKSzVyPUSuNVQ1KM7:TR?=	NUXlUG1GW0GQR1XS
CA46	NGHGO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;JTWM2OD12LkG2NVA1KM7:TR?=	M{H6S3NCVkeHUh?=
CHL-1	MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3sTWM2OD12LkG4PVYyKM7:TR?=	MXvTRW5ITVJ?
TE-10	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7hW\|JKSzVyPUSuNlI5QDdizszN	MmrtV2FPT0WU
NCI-H1734	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHLTWM2OD12LkK2Olk2KM7:TR?=	MmXtV2FPT0WU
DV-90	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fkNWlEPTB;ND6yPVM6PyEQvF2=	M{ToOHNCVkeHUh?=
MOLT-16	MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TpN2lEPTB;ND6zNVAyPiEQvF2=	MUDTRW5ITVJ?
HuCCT1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PEPWlEPTB;ND6zN\|czOyEQvF2=	NW[3clVMW0GQR1XS
A3-KAW	NF\ZcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDUTWM2OD12LkO1OVUzKM7:TR?=	NFrDdW9USU6JRWK=
HOS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkT2TWM2OD12LkO4OVY4KM7:TR?=	M4GxOnNCVkeHUh?=
KS-1	NIfEXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTRwNEK0OVkh\|ryP	MmS5V2FPT0WU
SNU-423	NEPQWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv5UW1KSzVyPUSuOFI3QDVizszN	NYmydWFOW0GQR1XS
BC-3	M{\MfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTRwNEO0O\|ch\|ryP	NH:zO\|RUSU6JRWK=
SCC-9	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTRwNESyPVkh\|ryP	NVrrR3kxW0GQR1XS
C8166	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLSTWM2OD12LkS3O\|U{KM7:TR?=	M1PLfHNCVkeHUh?=
NCI-H358	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXqdHJKSzVyPUSuOFg2OzJizszN	M1XpeXNCVkeHUh?=
GT3TKB	NVnPU4ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvqTWM2OD12LkS4PFIzKM7:TR?=	Ml7kV2FPT0WU
NCI-SNU-1	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGD2bW9KSzVyPUSuOFk4ODFizszN	NWS3bpNPW0GQR1XS
Ca9-22	NIGzdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTyUGJ3UUN3ME20MlU2PTF4IN88US=>	M1z4UXNCVkeHUh?=
L-363	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTRwNUW5PVYh\|ryP	NYTQeJBVW0GQR1XS
Calu-1	NYDtUnlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nqNWlEPTB;ND61PFcxPyEQvF2=	MW\TRW5ITVJ?
OE19	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;lVpJKSzVyPUSuOlMyPDVizszN	MlTIV2FPT0WU
COR-L23	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrUcmZKSzVyPUSuOlczQCEQvF2=	NUXONlVlW0GQR1XS
A431	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nX[WlEPTB;ND62PFIzQCEQvF2=	NIXCfnFUSU6JRWK=
MKN1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLI[ldKSzVyPUSuO\|A3PjVizszN	M{\4dXNCVkeHUh?=
SH-4	M1uxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnWTWM2OD12LkeyOlM{KM7:TR?=	NXTvW\|RtW0GQR1XS
SNB75	M2rh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYC2bY9EUUN3ME20Mlc1PjZizszN	MlHaV2FPT0WU
SW780	NXLafpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoruTWM2OD12Lke2PFQ6KM7:TR?=	MmK2V2FPT0WU
GOTO	M1TwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjPTWM2OD12Lke5Nlk{KM7:TR?=	MXzTRW5ITVJ?
U-266	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIX4PHVKSzVyPUSuPVQ6OTlizszN	MnvNV2FPT0WU
KURAMOCHI	M2HqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrDTWM2OD13LkCyPFM1KM7:TR?=	M2DKRXNCVkeHUh?=
NMC-G1	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPCTWM2OD13LkC5NVM6KM7:TR?=	NUDpVG1iW0GQR1XS
COLO-684	NUi0eXZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDRSG1KSzVyPUWuNlU{PzFizszN	NXS4UYVGW0GQR1XS
NTERA-S-cl-D1	MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHITWM2OD13LkK5NlE5KM7:TR?=	M{\QSnNCVkeHUh?=
RD	NGLMfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3pWHZKSzVyPUWuNlk4PzFizszN	MoLpV2FPT0WU
A2058	NGTYU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLOTWM2OD13LkOwOFM5KM7:TR?=	NVzTdnlQW0GQR1XS
NCI-H2009	NF\FfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvSTWM2OD13LkOwOVM5KM7:TR?=	M2DY[nNCVkeHUh?=
8-MG-BA	M2ixOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m5V2lEPTB;NT6zO\|A4PyEQvF2=	M4nHSXNCVkeHUh?=
LC4-1	NVr5dZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTiTWM2OD13LkO5N\|A{KM7:TR?=	M1vLTXNCVkeHUh?=
A101D	M2C1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTVwM{m2PFkh\|ryP	M{ni[XNCVkeHUh?=
ES8	NEfOT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHi1OJVKSzVyPUWuOFE1ODlizszN	Mn7LV2FPT0WU
SF126	MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLkTWM2OD13LkSxOFY2KM7:TR?=	MVjTRW5ITVJ?
GDM-1	M{XEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvvTWM2OD13LkSxO\|gyKM7:TR?=	Mm[0V2FPT0WU
TE-6	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTVwNES1Olkh\|ryP	M1PpV3NCVkeHUh?=
SR	NXPHUYxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\LSWNDUUN3ME21MlU{PjR3IN88US=>	NITpOJNUSU6JRWK=
HOP-62	NEPK[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rUOmlEPTB;NT61Olg5PyEQvF2=	NGTZO4NUSU6JRWK=
HCC2157	MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTVwNU[4PVYh\|ryP	NWDQe2loW0GQR1XS
TE-15	NV3Qeo4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjMdYVKSzVyPUWuOVc4PzlizszN	NEfGbHJUSU6JRWK=
BFTC-905	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\pTlQ5UUN3ME21MlYxPDJzIN88US=>	M1HHdHNCVkeHUh?=
TE-9	Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLuZnNKSzVyPUWuOlE4QDhizszN	MV;TRW5ITVJ?
647-V	NEDWNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Wx[GlEPTB;NT62NlA1OiEQvF2=	NHTv[pFUSU6JRWK=
KG-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4naVmlEPTB;NT63OFAxPSEQvF2=	NHH1RXlUSU6JRWK=
KYSE-510	NEj4V4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TycWlEPTB;NT63PVU5OSEQvF2=	M3HHW3NCVkeHUh?=
SK-MES-1	M{P3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELrOVBKSzVyPUWuPFU5QTFizszN	Mn;OV2FPT0WU
OVCAR-3	NFPWUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjjNFdKSzVyPUWuPFgzODZizszN	MV7TRW5ITVJ?
LB1047-RCC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTMenVKSzVyPUWuPVAyPDhizszN	NGLnW\|ZUSU6JRWK=
HEL	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD1UIZKSzVyPU[uNFIyQDhizszN	M4exZ3NCVkeHUh?=
KARPAS-45	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTZwMEO3PFch\|ryP	M2r1fXNCVkeHUh?=
NCI-H1304	NFfr[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjGe5lNUUN3ME22MlEzPDl5IN88US=>	MVPTRW5ITVJ?
PC-3	NHT3eWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlf2TWM2OD14LkGzNFczKM7:TR?=	NGHueZZUSU6JRWK=
Calu-3	M1L3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIm1cm1KSzVyPU[uNVQ3QDlizszN	M{fkUXNCVkeHUh?=
NCI-H1648	NIrESWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe3cVNKSzVyPU[uNVUyPiEQvF2=	MX7TRW5ITVJ?
HSC-3	NYntXZlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITXVJFKSzVyPU[uNVc{QTZizszN	NUP2U4xqW0GQR1XS
COLO-824	NUHtO5JJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3y3O2lEPTB;Nj6yO\|g3QCEQvF2=	MVfTRW5ITVJ?
COLO-680N	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fDOWlEPTB;Nj6zO\|Y{QCEQvF2=	NUXnS4t5W0GQR1XS
SK-NEP-1	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\mTWM2OD14LkSwN\|Yh\|ryP	MWfTRW5ITVJ?
SCC-25	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTZwNEK0PVMh\|ryP	MV;TRW5ITVJ?
SF295	M3;nZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rNXWlEPTB;Nj60OFk5KM7:TR?=	NFm3U\|dUSU6JRWK=
no-10	NFHTOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:0fGlEPTB;Nj60O\|g1KM7:TR?=	NV7xN2VqW0GQR1XS
NCI-H838	M3OyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3oc3FEUUN3ME22MlUyPzB\|IN88US=>	M1fDbnNCVkeHUh?=
M059J	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnvO\|NKSzVyPU[uOVU3OjVizszN	NVHRUpBCW0GQR1XS
Calu-6	NIXE[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfwWJBPUUN3ME22MlY2PDN3IN88US=>	MlLDV2FPT0WU
TE-12	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXXTWM2OD14LkeyN\|c4KM7:TR?=	M3PGUnNCVkeHUh?=
639-V	NEjqUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHiTWM2OD14Lke1NVI4KM7:TR?=	Mkf1V2FPT0WU
ESS-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;LWmlEPTB;Nj63OlA4OiEQvF2=	M4nMWHNCVkeHUh?=
C-4-II	NVL2TGt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXK0cY5FUUN3ME22Mlg{OTF5IN88US=>	NFm5ZlhUSU6JRWK=
23132-87	NWfvd\|N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmO2TWM2OD14LkmwPVAyKM7:TR?=	M4\LcXNCVkeHUh?=
MEG-01	NXnBcVhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1v4O2lEPTB;Nj65N\|U1PiEQvF2=	MnjvV2FPT0WU
GI-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\MTWM2OD14Lkm0N\|Q5KM7:TR?=	M4fCeXNCVkeHUh?=
NCI-H2347	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUS5VFl{UUN3ME22Mlk1PzF3IN88US=>	MWLTRW5ITVJ?
MS-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHmcVZKSzVyPU[uPVUyQTJizszN	MYLTRW5ITVJ?
SK-MEL-30	MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTZwOU[zNVUh\|ryP	M17sT3NCVkeHUh?=
YKG-1	NVr4XFFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TDRmlEPTB;Nz6wNlY4QCEQvF2=	NGnOSZJUSU6JRWK=
HT-3	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTdwMEO0PUDPxE1?	M{XDXnNCVkeHUh?=
NCI-H2126	NVjHU2VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInBOZpKSzVyPUeuNFk4QTFizszN	NUP1XItsW0GQR1XS
GI-ME-N	M4qzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTdwMU[5NFYh\|ryP	MkOxV2FPT0WU
LB771-HNC	NG\uOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mme2TWM2OD15LkG4NFM5KM7:TR?=	NGjHToRUSU6JRWK=
LCLC-97TM1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MomzTWM2OD15LkKxNlc{KM7:TR?=	NWS0OpUxW0GQR1XS
HO-1-N-1	MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP4TWM2OD15LkK0NFI1KM7:TR?=	NVfobGZyW0GQR1XS
HCC1143	NELOVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfiOIJKSzVyPUeuN\|c5QThizszN	MV;TRW5ITVJ?
HuO9	NI\4RphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e5VmlEPTB;Nz60PFc6PCEQvF2=	NIHpeXNUSU6JRWK=
IST-SL2	M1LZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3ucVgxUUN3ME23MlUzOjd{IN88US=>	M{DMPXNCVkeHUh?=
MLMA	M{jPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13Ec2lEPTB;Nz61OFY5QSEQvF2=	MYHTRW5ITVJ?
22RV1	M1TsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\RcGlEPTB;Nz62O\|k4PSEQvF2=	MXnTRW5ITVJ?
ONS-76	NH;JbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zqbGlEPTB;Nz62PVQyPiEQvF2=	NHj1R5VUSU6JRWK=
ECC12	NXy1R5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnERpVKSzVyPUeuO\|I6ODFizszN	MlnHV2FPT0WU
HT-1080	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILjPHRKSzVyPUeuO\|g2PTVizszN	MorLV2FPT0WU
SF268	NGjkR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz6XopNUUN3ME23Mlg{PTZizszN	NHy1TpdUSU6JRWK=
COLO-800	NUW1eVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoqzTWM2OD15LkmwOlg2KM7:TR?=	NIq3eWVUSU6JRWK=
BB30-HNC	NFSzSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;leIFKSzVyPUeuPVQ2PTNizszN	M133bHNCVkeHUh?=
CAKI-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRThwME[1NlEh\|ryP	M37Uc3NCVkeHUh?=
GCIY	NGXFeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUflcY05UUN3ME24MlI{PzF\|IN88US=>	MXXTRW5ITVJ?
MKN28	M{S3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkO2TWM2OD16LkK0OVk5KM7:TR?=	MofmV2FPT0WU
IPC-298	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorVTWM2OD16LkK3O\|A6KM7:TR?=	M3e1SHNCVkeHUh?=
NCI-H1650	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRThwMkmxPFUh\|ryP	MX;TRW5ITVJ?
KP-N-YS	M1jHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHIO3lYUUN3ME24MlI6OzB6IN88US=>	NWr0dW9tW0GQR1XS
J82	M3;ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TnT2lEPTB;OD6zOFEzPCEQvF2=	MoXuV2FPT0WU
SK-HEP-1	NX7DN3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELUepdKSzVyPUiuN\|U4OjNizszN	MWLTRW5ITVJ?
PANC-03-27	M2\zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NET0cFhKSzVyPUiuN\|Y6OiEQvF2=	MoLMV2FPT0WU
KP-4	NEX5fphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLMTWM2OD16LkSxPFU{KM7:TR?=	MoS4V2FPT0WU
RERF-LC-MS	M{PyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRThwNEi1PVUh\|ryP	MXXTRW5ITVJ?
C-33-A	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRThwNkG1Nlkh\|ryP	NEex[YtUSU6JRWK=
PA-1	NW\pcmRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRThwNk[2PVQh\|ryP	MYrTRW5ITVJ?
TE-5	NEXjcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrPPZVKSzVyPUiuO\|AzQTZizszN	M3XRfXNCVkeHUh?=
MHH-PREB-1	M1fNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\NNmlEPTB;OD63N\|ExPyEQvF2=	NHjTb\|BUSU6JRWK=
C3A	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHOTWM2OD16Lke2OVYyKM7:TR?=	NX:xeWpJW0GQR1XS
SK-OV-3	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\Fc2lEPTB;OD63PVc4OiEQvF2=	Mn[2V2FPT0WU
AM-38	MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRThwOEC0N\|kh\|ryP	NXHoSXJVW0GQR1XS
LoVo	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGO4V\|VKSzVyPUiuPVU2PjZizszN	NVTEbG1{W0GQR1XS
MKN45	NHnXTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTUTWM2OD16Lkm2NFY{KM7:TR?=	NVvPW3hRW0GQR1XS
NH-12	M2iyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTlwMEK1OFIh\|ryP	NIrUUWtUSU6JRWK=
CAMA-1	NUTKS5B2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTlwME[wNVIh\|ryP	M3fYU3NCVkeHUh?=
HT-29	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rkU2lEPTB;OT6xNlM4OyEQvF2=	MnrtV2FPT0WU
DMS-273	Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PIVGlEPTB;OT6xNlUh\|ryP	NVjGdpNYW0GQR1XS
NCI-H719	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvtRY5NUUN3ME25MlE5OzlzIN88US=>	MlHvV2FPT0WU
SF539	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TjTGlEPTB;OT6yNVA6QCEQvF2=	NXXqSWo2W0GQR1XS
Daoy	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfBSZlKSzVyPUmuNlQyPDNizszN	NIjpUlZUSU6JRWK=
HCC70	NGXLdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrSTWM2OD17LkK3N\|A6KM7:TR?=	NVLLS3lYW0GQR1XS
MFH-ino	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPSTWM2OD17LkK5NFA4KM7:TR?=	NYXsd4pwW0GQR1XS
UACC-62	M4Prfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nzOmlEPTB;OT6zO\|I6PyEQvF2=	M3nybnNCVkeHUh?=
C2BBe1	NFm3OlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTlwM{m2OVIh\|ryP	NFjBfIhUSU6JRWK=
KNS-42	M37QbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEOyTJdKSzVyPUmuOFM1ODdizszN	NFq0fJhUSU6JRWK=
SK-LMS-1	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTlwN{W1N\|Uh\|ryP	Mme0V2FPT0WU
SK-CO-1	NELye4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XKXWlEPTB;OT63OlI{PSEQvF2=	MmLyV2FPT0WU
SN12C	M4HIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTITWM2OD17Lke2PFA3KM7:TR?=	NY\PN5l4W0GQR1XS
HTC-C3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHUZZVKSzVyPUmuO\|c6QDRizszN	M4HMNXNCVkeHUh?=
OVCAR-4	NI[zb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzGXWNKSzVyPUmuPFQ5OjhizszN	MVvTRW5ITVJ?
CHP-126	M3X1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTlwOUOyPUDPxE1?	MVTTRW5ITVJ?
NCI-H716	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTlwOUOzNlIh\|ryP	M{jHNXNCVkeHUh?=
U-698-M	NWLh[2lsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[2eW1yUUN3ME25Mlk6PyEQvF2=	MlKyV2FPT0WU
EFO-21	M1LBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7nTWM2OD1zMD6wNFk{KM7:TR?=	Ml\uV2FPT0WU
RXF393	M4H0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTFyLkGzPVIh\|ryP	NGi3dYNUSU6JRWK=
ChaGo-K-1	NIXkb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rNfmlEPTB;MUCuNVc4PiEQvF2=	M{izeXNCVkeHUh?=
SJRH30	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXWXWVKUUN3ME2xNE4yQDR2IN88US=>	Mnr4V2FPT0WU
LU-65	NHXGVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrkToFKSzVyPUGwMlI6PDNizszN	NHfrS2NUSU6JRWK=
OS-RC-2	MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTFyLkOyNlch\|ryP	MnL6V2FPT0WU
YT	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHleZhKSzVyPUGwMlQxODFizszN	MYHTRW5ITVJ?
COLO-679	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkD6TWM2OD1zMD60Nlg2KM7:TR?=	NH;wV\|NUSU6JRWK=
CAS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XUeWlEPTB;MUCuOFYxQCEQvF2=	NX;KSIVCW0GQR1XS
NCI-H2052	NYf3PVd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTFyLkWxNFUh\|ryP	NFnv[4RUSU6JRWK=
NCI-H2452	NUXvT49WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nvNGlEPTB;MUCuOlE5OSEQvF2=	MVrTRW5ITVJ?
SW13	NYXVUHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[0e\|hIUUN3ME2xNE43Ozd2IN88US=>	MlvPV2FPT0WU
HuP-T4	NYDLdWJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjvOZFKSzVyPUGwMlcxPjhizszN	MUPTRW5ITVJ?
UMC-11	M4PNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjYU4dJUUN3ME2xNE46Ozd\|IN88US=>	NF3KZXJUSU6JRWK=
EGI-1	NFzHU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3VTWM2OD1zMD65OFU2KM7:TR?=	MlLGV2FPT0WU
JiyoyeP-2003	NGHGc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojzTWM2OD1zMT6wPFkzKM7:TR?=	NUXQc3NIW0GQR1XS
J-RT3-T3-5	MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7pdmo2UUN3ME2xNU4yOjB7IN88US=>	NX3yUZViW0GQR1XS
DoTc2-4510	M1fLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjFTWM2OD1zMT6xN\|g6KM7:TR?=	M4GzbXNCVkeHUh?=
HLE	NUHPOm9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HnTWlEPTB;MUGuNlEyQSEQvF2=	NHjwXoxUSU6JRWK=
SW626	NHvvdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLZTWM2OD1zMT6yPFg6KM7:TR?=	M4flUnNCVkeHUh?=
COR-L105	NVvGZZJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYKwZpdyUUN3ME2xNU4{OjN5IN88US=>	MnTqV2FPT0WU
ES6	NYT2XotFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFzLkW3OkDPxE1?	NVn5OHdUW0GQR1XS
SNU-449	MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7LRZhsUUN3ME2xNU43ODd{IN88US=>	MXvTRW5ITVJ?
GR-ST	M3zDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Cwe2lEPTB;MUGuOlE5OSEQvF2=	MnzSV2FPT0WU
BL-41	M3\1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHBTWM2OD1zMT63NVc{KM7:TR?=	NUC1ZmNVW0GQR1XS
GB-1	NGKwcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjxO5RTUUN3ME2xNU44PjF7IN88US=>	NUPrN3ZFW0GQR1XS
COLO-320-HSR	M2fnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXv0UmM6UUN3ME2xNU45PTF7IN88US=>	MnfaV2FPT0WU
L-540	NGDrSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTFzLki5PUDPxE1?	Mom4V2FPT0WU
NCI-H69	NWj1ZXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:xfWlEPTB;MUKuNFE{QSEQvF2=	NVHndo1zW0GQR1XS
769-P	NXfHSI5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq0TWM2OD1zMj6wNVkh\|ryP	MXvTRW5ITVJ?
A172	NV;2cHJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHk[ldnUUN3ME2xNk4yOjB5IN88US=>	MoTIV2FPT0WU
CAL-27	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLSWpVKSzVyPUGyMlE{PjlizszN	MoHzV2FPT0WU
NCI-H1437	NEi4Z29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXuTWM2OD1zMj6xOFQ4KM7:TR?=	MV\TRW5ITVJ?
REH	NUHmVpRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTETZhNUUN3ME2xNk4yPTd\|IN88US=>	MVXTRW5ITVJ?
KINGS-1	M3jOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTF{LkO0NlEh\|ryP	NF;KcZZUSU6JRWK=
NCI-H1792	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrTPWxKSzVyPUGyMlM5PTFizszN	NFriPJZUSU6JRWK=
SK-MM-2	NHv4N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfNNpBKSzVyPUGyMlQxQDdizszN	NGjmNFlUSU6JRWK=
8505C	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nnPWlEPTB;MUKuOlEzKM7:TR?=	NH3vc3VUSU6JRWK=
HAL-01	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TjTWlEPTB;MUKuOlE4PCEQvF2=	MVrTRW5ITVJ?
NCI-H2141	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYCzfnJQUUN3ME2xNk43PThizszN	MVzTRW5ITVJ?
HCC1806	M2rQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTF{Lk[5OVIh\|ryP	NESzd\|lUSU6JRWK=
LU-134-A	NYrEVFNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIm2UVJKSzVyPUGyMlk{KM7:TR?=	M3\ZWXNCVkeHUh?=
HT	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXU[oRsUUN3ME2xNk46PDN5IN88US=>	MUPTRW5ITVJ?
OE33	NWTHRmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTF{Lkm0OVYh\|ryP	NGfRb3VUSU6JRWK=
ES4	NYPHNmhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHP5U3BKSzVyPUGyMlk1QDdizszN	NUTM[XlOW0GQR1XS
SW948	NHT3bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\C[4NXUUN3ME2xN{4xOTNizszN	NWruUod7W0GQR1XS
LB2241-RCC	NV;5SWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLkTYlKSzVyPUGzMlE1PjlizszN	MVXTRW5ITVJ?
CCF-STTG1	M4n5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHtTWM2OD1zMz60NFM6KM7:TR?=	Mn3MV2FPT0WU
RPMI-8402	NXKzfVd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTF\|LkWwN\|Eh\|ryP	NHLwO2dUSU6JRWK=
DEL	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e0U2lEPTB;MUOuOVUxOyEQvF2=	MoOwV2FPT0WU
NB5	NIn0PFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGf2OnBKSzVyPUGzMlU2ODNizszN	NXe0Z4VkW0GQR1XS
NUGC-3	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3C[mZYUUN3ME2xN{44PDV\|IN88US=>	NEDyW3FUSU6JRWK=
CAL-72	NXm0RlRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTF2LkG5NFYh\|ryP	MmHJV2FPT0WU
VMRC-RCZ	NFPBenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlG4TWM2OD1zND6yN\|Yh\|ryP	NGrTbFRUSU6JRWK=
YAPC	NW\rb5JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGOySXpKSzVyPUG0MlI1ODdizszN	MX;TRW5ITVJ?
ES5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX60PVVKUUN3ME2xOE4zPTl7IN88US=>	MoHxV2FPT0WU
CAL-12T	NXPmVlFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjPdW8xUUN3ME2xOE41OzN4IN88US=>	MkL2V2FPT0WU
GAMG	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli0TWM2OD1zND61OVc4KM7:TR?=	MljPV2FPT0WU
BT-20	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknyTWM2OD1zND65N\|g1KM7:TR?=	M3OxPXNCVkeHUh?=
KALS-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\v[oVzUUN3ME2xOU4xOTV6IN88US=>	MWrTRW5ITVJ?
LS-123	M{X3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTF3LkCxOlUh\|ryP	NFXPPYZUSU6JRWK=
LK-2	NGrBVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1v3b2lEPTB;MUWuNFg3OiEQvF2=	MnP1V2FPT0WU
NCI-H1770	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTF3LkK4Olgh\|ryP	NV;ISGNDW0GQR1XS
MIA-PaCa-2	NXX2b2FWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIroN3pKSzVyPUG1MlQyPjNizszN	NEnSXo5USU6JRWK=
DB	NX3vNJZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrKZ5E4UUN3ME2xOU43QTRzIN88US=>	NH7nbW1USU6JRWK=
Becker	NEj0PYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XiUWlEPTB;MUWuPFkzPiEQvF2=	MnrXV2FPT0WU
HT-144	NEjobXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TZXWlEPTB;MUWuPVQ6PyEQvF2=	NEG5RoxUSU6JRWK=
NCI-H2405	M3LHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7yWotKSzVyPUG2MlIzOThizszN	M1jPdXNCVkeHUh?=
TK10	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDyTWM2OD1zNj6zO\|QzKM7:TR?=	NFn1[o5USU6JRWK=
THP-1	MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PIUWlEPTB;MU[uOFY3PSEQvF2=	MVzTRW5ITVJ?
LB373-MEL-D	NXnqUXhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTF4Lk[xN\|gh\|ryP	M4DLZnNCVkeHUh?=
SJSA-1	M{LIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDJTWM2OD1zNj65NlE6KM7:TR?=	NWPTWnAyW0GQR1XS
EB2	M3Pke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPK[VgzUUN3ME2xO{44PDJ4IN88US=>	MoLuV2FPT0WU
MN-60	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYCy[\|dWUUN3ME2xO{44QTN4IN88US=>	M{nwO3NCVkeHUh?=
A253	NHf4RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTF5LkiyOUDPxE1?	MVTTRW5ITVJ?
CESS	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDndFJKSzVyPUG3Mlk{OjZizszN	MnfjV2FPT0WU
EW-11	NWTiNW5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzzOpllUUN3ME2xO{46QTV6IN88US=>	Mor0V2FPT0WU
TE-8	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PNTGlEPTB;MUiuNFY3QSEQvF2=	MXLTRW5ITVJ?
UACC-257	NEPtR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PkdGlEPTB;MUiuNlA3OiEQvF2=	NITBOpBUSU6JRWK=
NCI-H226	NU\mNoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTzTYlYUUN3ME2xPE45Ojl7IN88US=>	M3jYbHNCVkeHUh?=
NCI-H748	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTF6Lki1PFUh\|ryP	MVTTRW5ITVJ?
NCI-H1299	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTF6Lki5NVgh\|ryP	MoHaV2FPT0WU
IST-MEL1	NWPGflg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTKPI1PUUN3ME2xPU4yPzV2IN88US=>	MWTTRW5ITVJ?
HCC1187	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1W1c2lEPTB;MUmuNVc6PiEQvF2=	MUXTRW5ITVJ?
HT-1376	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV25NIJOUUN3ME2xPU4zODJ7IN88US=>	MUXTRW5ITVJ?
SK-MEL-2	MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLqNphKSzVyPUG5MlIyPTVizszN	M1m1UnNCVkeHUh?=
U031	NVvGcJU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnmWZBKSzVyPUG5MlIzOTlizszN	NH:zfY9USU6JRWK=
NCI-H524	NXTlfJd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfPTWM2OD1zOT61O\|I2KM7:TR?=	NEXiOndUSU6JRWK=
KU812	NWKwbHkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTF7LkW5OFQh\|ryP	NV71Z5J3W0GQR1XS
NB10	NEHZOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTF7Lk[yOlgh\|ryP	NGnZfG9USU6JRWK=
NOS-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\oN2ZKSzVyPUKwMlE2PzdizszN	MUjTRW5ITVJ?
EW-7	NF6zS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvzcmFIUUN3ME2yNE4yPjJ6IN88US=>	NVHwfXlbW0GQR1XS
Raji	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\N[mlEPTB;MkCuNlU3QCEQvF2=	MUfTRW5ITVJ?
LB2518-MEL	MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvGeHFwUUN3ME2yNE4{QTV\|IN88US=>	MmS0V2FPT0WU
PANC-10-05	NEL0SGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4njfmlEPTB;MkCuOFYyOyEQvF2=	NVK1VIE{W0GQR1XS
MZ2-MEL	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInSNYdKSzVyPUKwMlU5OTRizszN	NIm0cVRUSU6JRWK=
MFE-280	NX[w[4w2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJzLkOxPFgh\|ryP	M4rTfnNCVkeHUh?=
RKO	NVPUXopST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7YSlFKSzVyPUKxMlMzODJizszN	NVjMTIh{W0GQR1XS
KMOE-2	M4HPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPDb3hKSzVyPUKxMlMzQDhizszN	NVPUU4ZwW0GQR1XS
K5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLERYJKSzVyPUKxMlM5QTNizszN	MYDTRW5ITVJ?
NCI-H64	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2myOWlEPTB;MkGuOFc2PiEQvF2=	MVrTRW5ITVJ?
K-562	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTJzLkS5O\|Eh\|ryP	M3S0cXNCVkeHUh?=
HCE-T	Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTJzLkWwPVQh\|ryP	Mk\JV2FPT0WU
COLO-792	NHPrTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MormTWM2OD1{MT61PFI4KM7:TR?=	NHjkNGNUSU6JRWK=
PFSK-1	NVGzWm5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHsVlRKSzVyPUKxMlY5OzdizszN	MlT1V2FPT0WU
DOK	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HJPWlEPTB;MkGuO\|Y5PyEQvF2=	MoPZV2FPT0WU
NCI-H1882	NXLpdW8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;xTWM2OD1{MT64OVk3KM7:TR?=	MXrTRW5ITVJ?
KNS-81-FD	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljqTWM2OD1{MT64OlMyKM7:TR?=	MYPTRW5ITVJ?
OCUB-M	NGDybVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLuTWM2OD1{MT65Olg5KM7:TR?=	MkfsV2FPT0WU
NCI-H1694	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXy0eHJFUUN3ME2yNU46QDZ\|IN88US=>	MnHsV2FPT0WU
LS-513	NWSxTmpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPmTWM2OD1{Mj6wN\|Y4KM7:TR?=	NV31W2FKW0GQR1XS
NCI-H2122	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfSTWM2OD1{Mj6xOlc4KM7:TR?=	MlGyV2FPT0WU
IMR-5	M{Dxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILDZ3dKSzVyPUKyMlI5PyEQvF2=	NHPkVGhUSU6JRWK=
SNU-C2B	M4\Cfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT1W4hpUUN3ME2yNk43PzR4IN88US=>	MUjTRW5ITVJ?
A498	M1H0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2j3O2lEPTB;MkKuPFE4PyEQvF2=	NGrjOnBUSU6JRWK=
NCI-H727	NFj5TpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPmT3liUUN3ME2yNk45QDN4IN88US=>	MlP2V2FPT0WU
SW1573	NYTFVlhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTJ\|LkC2OFYh\|ryP	MonZV2FPT0WU
RO82-W-1	M4jNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHMTWM2OD1{Mz6yOVEyKM7:TR?=	NUHB[21IW0GQR1XS
SKG-IIIa	NYn1cGh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPQU3BmUUN3ME2yN{4{PTR4IN88US=>	Mm\iV2FPT0WU
MC-CAR	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInoNJdKSzVyPUKzMlUyQDNizszN	NEn0WIZUSU6JRWK=
NCI-H446	M{OzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX:zVINsUUN3ME2yN{43ODl\|IN88US=>	NFfwPY1USU6JRWK=
PC-14	NWHRbJNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLSOpFKSzVyPUKzMlY3OjNizszN	M4DZVHNCVkeHUh?=
TGBC1TKB	NXPRWHpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPQd5JKSzVyPUKzMlc1PjFizszN	MnzzV2FPT0WU
EFM-19	M2TXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HRNGlEPTB;MkSuNVg1PCEQvF2=	NHW1bXBUSU6JRWK=
SK-N-DZ	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjITpBjUUN3ME2yOE41QTd5IN88US=>	MYDTRW5ITVJ?
NCI-H661	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXUTWM2OD1{ND61NlE4KM7:TR?=	NHjUU4pUSU6JRWK=
SW1990	M3nkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGOwTItKSzVyPUK0MlU5QDNizszN	NIDM[5JUSU6JRWK=
SW684	M{jaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTLeJlvUUN3ME2yOE44PjJ2IN88US=>	MY\TRW5ITVJ?
Ca-Ski	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHicIlWUUN3ME2yOE46OjN5IN88US=>	MV;TRW5ITVJ?
TGW	NUHtZ\|RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\MV2h2UUN3ME2yOU4zOzN5IN88US=>	NI[2UXRUSU6JRWK=
CaR-1	NWPVU2dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTJ3LkO1O{DPxE1?	M2W3UXNCVkeHUh?=
D-247MG	NEnoRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LDZmlEPTB;MkWuOFc1OyEQvF2=	MYTTRW5ITVJ?
CCRF-CEM	NWfWNIx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Kz[GlEPTB;MkWuO\|Q2QSEQvF2=	M1LxbnNCVkeHUh?=
CAPAN-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfRWYVKSzVyPUK1Mlc2ODFizszN	M3WyRnNCVkeHUh?=
CP50-MEL-B	NYrudGJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvYeXBOUUN3ME2yOU46QTBzIN88US=>	NHTXWGtUSU6JRWK=
FADU	MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPFNmpvUUN3ME2yOk42OTV{IN88US=>	MYLTRW5ITVJ?
Daudi	M1TVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rJN2lEPTB;Mk[uOVE2QCEQvF2=	M3zLUnNCVkeHUh?=
U-87-MG	NFqzOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTJ4LkWzNFUh\|ryP	Mn;3V2FPT0WU
DSH1	NG\qV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPlTWJ1UUN3ME2yOk42PDB4IN88US=>	MnvjV2FPT0WU
KYSE-520	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoX6TWM2OD1{Nj61OVU{KM7:TR?=	MYjTRW5ITVJ?
HuH-7	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\4dXBmUUN3ME2yOk46ODh4IN88US=>	NVu3O3llW0GQR1XS
U-2-OS	NFHYNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7oTWM2OD1{Nz6wNlcyKM7:TR?=	MknCV2FPT0WU
LU-99A	M{fHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHSUoxKSzVyPUK3MlE4PTRizszN	NX7zUYpCW0GQR1XS
T98G	NFGwb\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTJ5LkG5O\|Mh\|ryP	NYrOfWsxW0GQR1XS
MZ7-mel	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnTTWM2OD1{Nz61OVQ5KM7:TR?=	MnK1V2FPT0WU
SNU-C1	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrWenJKSzVyPUK3MlY1QTFizszN	MlLxV2FPT0WU
MDA-MB-175-VII	NH\Ic4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;N[lhKSzVyPUK3MlY6PzVizszN	NUDvWIJpW0GQR1XS
HuP-T3	NYDXXZh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUX1b\|ZpUUN3ME2yPE4xPDl3IN88US=>	NG\kV\|dUSU6JRWK=
T-24	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnmwTWM2OD1{OD6xPVI2KM7:TR?=	M3XDSHNCVkeHUh?=
HDLM-2	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDQN2RKSzVyPUK4MlI1PTlizszN	MUHTRW5ITVJ?
NCI-H1651	M4GwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPYTWM2OD1{OD6yOVkzKM7:TR?=	M3nUeHNCVkeHUh?=
SK-N-AS	NGO0cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmf4TWM2OD1{OD6zNVcyKM7:TR?=	NUTxWJNFW0GQR1XS
NY	Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\WWWtKSzVyPUK4MlY2PzlizszN	NUDoU40yW0GQR1XS
D-283MED	M2GzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPqTWM2OD1{OD64O\|A5KM7:TR?=	MmPBV2FPT0WU
KLE	NHLzdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfzelJKSzVyPUK4Mlk6ODZizszN	M3XNZXNCVkeHUh?=
NCI-H28	M{nrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7QTWM2OD1{OT6wNVIh\|ryP	MYfTRW5ITVJ?
TE-1	MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXvUHdKSzVyPUK5MlIyPjdizszN	NXTQOlFFW0GQR1XS
SK-MEL-24	M4K3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTJ7LkW0OlYh\|ryP	NVS5TJFMW0GQR1XS
CAL-54	NYnHe4FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTJ7Lk[wOFYh\|ryP	NUXxNGJ1W0GQR1XS
A673	M1jiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3ofGdKSzVyPUK5Mlc{OiEQvF2=	NELkVXlUSU6JRWK=
HEC-1	NYjjOXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjlTWM2OD1\|MD6wNFU{KM7:TR?=	NFjpdI5USU6JRWK=
LS-411N	NYfhfYdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfKSZJKSzVyPUOwMlE1PzVizszN	NIrFXWFUSU6JRWK=
SW962	M1PORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfSUlVKSzVyPUOwMlI1PzdizszN	NHPkTGxUSU6JRWK=
OVCAR-8	NFyzOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[ySXFKSzVyPUOwMlY4QTRizszN	MXnTRW5ITVJ?
NCI-H630	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\OTWM2OD1\|MD64PVU{KM7:TR?=	M3nFN3NCVkeHUh?=
D-263MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHKTWM2OD1\|MT6wOFI1KM7:TR?=	NGXQenlUSU6JRWK=
NCI-H596	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTNzLkC2NlEh\|ryP	M2fsfXNCVkeHUh?=
BB49-HNC	NH7IT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Po[2lEPTB;M{GuNVEzKM7:TR?=	NXP3c4hUW0GQR1XS
KYSE-70	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3JTWM2OD1\|MT6zNFA5KM7:TR?=	MoPwV2FPT0WU
LAN-6	M2nPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfhbJlKSzVyPUOxMlQ6QTJizszN	M{CxT3NCVkeHUh?=
NCI-H2228	MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTNzLkW2NlUh\|ryP	NWrkWVVGW0GQR1XS
SW620	NX;EPVlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXaTWM2OD1\|MT62Nlg{KM7:TR?=	MnL2V2FPT0WU
KM-H2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLsNWc{UUN3ME2zNU44OzB4IN88US=>	NGCyemJUSU6JRWK=
DJM-1	NHHVOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfifW1GUUN3ME2zNk4yOzh4IN88US=>	NGDuUYJUSU6JRWK=
SW48	NGS1TYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3niSGlEPTB;M{KuN\|gzPSEQvF2=	NX;WXJV6W0GQR1XS
NCI-H1793	M1rCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTN{Lk[xOlMh\|ryP	M1rWfHNCVkeHUh?=
LU-165	NYfBOGRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\mS\|lkUUN3ME2zN{4xODhizszN	NETCco9USU6JRWK=
EHEB	M{nONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTN\|LkC0PVQh\|ryP	NUTsOY1DW0GQR1XS
NCI-H441	NYXxTnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGftV21KSzVyPUOzMlIzOzVizszN	MXjTRW5ITVJ?
LOXIMVI	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrFTWM2OD1\|Mz6zOlc6KM7:TR?=	NVm1fY1wW0GQR1XS
MC-IXC	M33VZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHCRWVKSzVyPUOzMlU3PTVizszN	Mon2V2FPT0WU
NCI-H522	NV\4UlZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTN\|Lk[1OEDPxE1?	M1v2THNCVkeHUh?=
IA-LM	NYm0WYFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXJW2RKSzVyPUOzMlY4PDZizszN	MoDqV2FPT0WU
NCI-H1417	NIX6VZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1y0OmlEPTB;M{OuPVU5PSEQvF2=	NIrSOWxUSU6JRWK=
HCC2218	NHrxbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDoNpM{UUN3ME2zOU4zOTh3IN88US=>	NFO0SGNUSU6JRWK=
HC-1	NIL2dHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELZUGtKSzVyPUO1MlQxOjRizszN	M{P5V3NCVkeHUh?=
HH	NVS3ephRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfHUIJKSzVyPUO1MlQyPDFizszN	MX\TRW5ITVJ?
EFE-184	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;jTWM2OD1\|NT62PFI6KM7:TR?=	M3PqcHNCVkeHUh?=
NCI-H1355	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfTTWM2OD1\|NT63O\|E5KM7:TR?=	MlfxV2FPT0WU
BV-173	NHXjZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXkT3ZDUUN3ME2zOU45OjZ2IN88US=>	NGHNUI5USU6JRWK=
NEC8	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;tPGlEPTB;M{[uOFkzPCEQvF2=	NXjKe4lQW0GQR1XS
SW1463	NGC5T41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTN4Lk[1OlYh\|ryP	MVLTRW5ITVJ?
KYSE-140	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHCWmZKSzVyPUO2MlczQThizszN	NWC2PGJmW0GQR1XS
no-11	M{nHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvpSpBKSzVyPUO2Mlg2OzZizszN	NYfNfZl1W0GQR1XS
HCC1937	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nEOGlEPTB;M{euNFE2PCEQvF2=	MYHTRW5ITVJ?
LNCaP-Clone-FGC	NHr3RZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne5TWM2OD1\|Nz6xPVA{KM7:TR?=	M3fJfXNCVkeHUh?=
KARPAS-422	M{\Ucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzrS2lKSzVyPUO3MlQ1OzFizszN	M33l[HNCVkeHUh?=
RCM-1	NY\KdHFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vnfmlEPTB;M{euOVM2QCEQvF2=	NUn1W\|hUW0GQR1XS
A375	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTN5Lke2OFch\|ryP	MmTRV2FPT0WU
TGBC24TKB	NVrLUVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHiNHBqUUN3ME2zPE4xOjN7IN88US=>	M2m0WHNCVkeHUh?=
MDA-MB-453	M3XJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnW3TWM2OD1\|OT6wNlE5KM7:TR?=	Mnq0V2FPT0WU
Capan-2	NUjneWtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjUTFB3UUN3ME2zPU4xPTB7IN88US=>	NVKxfnRvW0GQR1XS
SW756	NFHnTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvLTWM2OD1\|OT61NFkyKM7:TR?=	M1TpfXNCVkeHUh?=
KU-19-19	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfEXVBKSzVyPUO5MlYzQDJizszN	M3zOTXNCVkeHUh?=
NCI-H2170	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX6cIJKSzVyPUO5Mlk6PzdizszN	MYfTRW5ITVJ?
COLO-678	NYLwPZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHKSllKSzVyPUSwMlU6PSEQvF2=	NIrud\|lUSU6JRWK=
PF-382	NV\tc2g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjpTWM2OD12MD63OFg4KM7:TR?=	MYjTRW5ITVJ?
OAW-42	NVzFdoRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTR{LkK5OFIh\|ryP	MnS2V2FPT0WU
LB996-RCC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTR{LkiwNFgh\|ryP	Mo\lV2FPT0WU
SAS	NGfVfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnG5TWM2OD12Mz60Nlg5KM7:TR?=	MVnTRW5ITVJ?
MRK-nu-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfmOotxUUN3ME20OE44PDF2IN88US=>	NWfpeoI3W0GQR1XS
EoL-1-cell	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofqTWM2OD12ND65NVM3KM7:TR?=	NWH5[3RtW0GQR1XS
NCI-H2342	NGnrTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjmO5RKSzVyPUS1MlEyOTdizszN	MkKxV2FPT0WU
NCI-H1703	NHzod3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{e4eGlEPTB;NE[uNFU6OiEQvF2=	MYPTRW5ITVJ?
NCI-H187	M{\zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrGTWM2OD12Nj6xPFY6KM7:TR?=	NFHmXJNUSU6JRWK=
CP66-MEL	NF\kN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLqTWM2OD12Nj6yO\|g6KM7:TR?=	M4PmdXNCVkeHUh?=
HCC1569	M4C5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTR4LkW5NVch\|ryP	NWnNNGpvW0GQR1XS
BL-70	M3jvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTR4Lke3N\|ch\|ryP	NHzyTotUSU6JRWK=
Saos-2	MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LrWGlEPTB;NEeuN\|EzOyEQvF2=	M3W2PHNCVkeHUh?=
LC-1F	NHPVcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq4TnNKSzVyPUS3MlYyODVizszN	MoD0V2FPT0WU
KY821	MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fMZWlEPTB;NEeuOlQ{PCEQvF2=	NYj1XY1sW0GQR1XS
PSN1	M4D6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGT2WIRKSzVyPUS4MlE1ODFizszN	NWTIWlBJW0GQR1XS
RT4	MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jHSmlEPTB;NEiuPFM4PyEQvF2=	NH\W[ldUSU6JRWK=
LS-1034	NXfWWFIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\kRXdKSzVyPUS4Mlg6PTRizszN	NVP4ZVhCW0GQR1XS
NCI-H1395	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonuTWM2OD12OT6wOFkzKM7:TR?=	MkHmV2FPT0WU
EKVX	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjmTWM2OD12OT62O\|MyKM7:TR?=	NFvBZmFUSU6JRWK=
IST-MES1	M4XiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXSxO\|VsUUN3ME20PU45QTR2IN88US=>	MmThV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FAK / FAK / p-Talin / Talin ; PubMed: 26530902 Cancer Res Dose response of PF-562271 on the phosphorylation of FAK-Y397 or Talin-S425 in PC3-mm2 cells. p-Src / Src / p-paxillin / Paxillin / ICAM-1 ; PubMed: 29417941 Acta Pharmacol Sin MDA-MB-231 cells transfected with FAK-specific siRNAs or treated for 12 h with PF-562271 at the indicated concentrations were subjected to immunoblotting with indicated antibodies.	26530902 29417941
Immunofluorescence	p-FAK; PubMed: 26530902 Cancer Res Immunostaining of PC3-mm2 cells showed that phosphorylated FAK is localized at focal adhesions (inset).	26530902
Growth inhibition assay	Cell viability; PubMed: 28953264 Nutrients MTT assay showed inhibition of cell proliferation and viability in HCT116 (B) and SW480 (D) cell lines treated with resveratrol and/or different concentrations of FAK-Inhibitor (PF-562271: 0.01, 0.1, 1, and 10 µM) cultured in monolayer for 12 h. Data shown are representative of three independent sets of experiments. Values were compared with the control and statistically significant values with p < 0.05 are designated by an asterisk () and p < 0.01 are designated by two asterisks (*).	28953264

In vivo

PF-562271 (< 33 mg/kg p.o.) inhibits FAK phosphorylation in tumors in a dose- and time-dependent manner in U87MG-bearing mice. PF-562271 (50 mg/kg p.o. bid) results in 86% tumor growth inhibition in BxPc3 xenografts mice and 45% tumor growth inhibition in PC3-M xenografts mice. PF-562271 (25 mg/kg, bid) results in 2-fold greater apoptosis in treated tumors in mice bearing H125 lung xenografts. ^[1] PF-562271 (33 mg/kg, p.o.) inhibits extensive movement of the tumor cells over 24 hours in mice. PF-562271 (33 mg/kg, p.o.) results in altered E-cadherin dynamics in mice, which correlates with reduced E-cadherin–dependent collective cell movement. ^[3] PF-562271 (25 mg/kg, p.o. bid) results in 62% tumor growth inhibition in PC3M-luc-C6 subcutaneuous local implant xenograft mouse model. ^[4] PF-562,271 (5 mg/kg, oral) results in significant and similar increases in osteocalcin and cancellous bone parameters and a decrease in tumor growth and signs of bone healing in rats implanted with MDA-MB-231 cells in the tibia. ^[5]

Protocol

Animal Research:^[1]	- Collapse Animal Models: Athymic female mice bearing BxPc3 or PC3-M xenografts. Dosages: 50 mg/kg Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL warmed (197.04 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	5 mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-562271 SDF

Molecular Weight	507.49
Formula	C₂₁H₂₀F₃N₇O₃S
CAS No.	717907-75-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

FAK Signaling Pathway Map

Related FAK Products

PND-1186 (VS-4718) ^New

PND-1186 (VS-4718, SR-2156) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. PND-1186 selectively promotes tumor cell apoptosis. Phase 1.
PF-431396 ^New

PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
PF-00562271 Besylate

PF-00562271 Besylate (PF-562271) is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
TAE226 (NVP-TAE226)

TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. TAE226 (NVP-TAE226) induces apoptosis.
PF-573228

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β. PF-573228 induces apoptosis.
PF-562271 HCl

PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Dasatinib

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-562271